We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We may also share information about your use of our site with our social media, advertising and analytics partners. Read more about our Privacy Policy.

I got it!

Mr Kandeepan Ganeshalingam Ganeshalingam

Executive Director Therapeutic Area Head Oncology European Clinical Development

Dr. Kandeepan Ganeshalingam received his medical degree from the University of Aberdeen and a Master of Science Degree from the Imperial College School of Medicine, University of London. He was also the Faraday Research fellow at the National Heart and Lung Institute, UK. Following
a 10 year career as a physician in the National Health Service Hospitals, UK, he joined the oncology product development team at Roche in 2007. In this role, he played a significant role in product development with several successful submissions to EMA and FDA. In 2010, he moved to Vifor Pharma, Switzerland to become the global head of medical and clinical drug safety, where he played a leadership role in clinical development, regulatory submissions and safety risk management. In 2012, he returned to Roche Product Development Medical Affairs as senior medical director, in immunology and was subsequently promoted to group medical
director in oncology, where he led the global medical team responsible for multiple haematology/oncology products. In this role, he was instrumental in building clinical trial collaborations with academic groups and external pharmaceutical companies. In 2016, he joined Merck Sharp Dohme as the executive director, oncology therapeutic area head, European
clinical development.

Kandeepan Ganeshalingam spoke at

2nd Annual Cancer Immunotherapy Summit Vonlanthen Grou... Sep 2017